Buy Levitra 20mg Online Safely

Levitra is a potent and selective inhibitor of cGMP-specific
phosphodiesterase type 5 (PDE5), which is responsible for the breakdown of cGMP in the cavernous
body. Levitra has a peripheral effect on erection. Sildenafil does not have
a direct relaxing effect on the cavernous body, but actively enhances the relaxing
effect of NO on this tissue. With the levitra health facts activation of the NO/cGMP pathway observed during sexual
arousal, PDE5 inhibition under the influence of Levitra leads to an increase
in cGMP levels in the cavernous body. In this regard , for the manifestation of a favorable pharmacological
the effect of Levitra requires sexual stimulation.

With a single oral administration of Levitra in doses up to 100 mg in healthy
volunteers, the drug did not cause clinically significant ECG changes. The maximum
decrease in systolic blood pressure in the supine position when the
drug was administered orally at a dose of 100 mg averaged 8.4 mmHg.
the decrease in diastolic blood pressure in the supine position was
5.5 mm Hg.

The decrease in blood pressure is explained by the vasodilating
effects of sildenafil, possibly due to an increase in the level of cGMP in smooth muscles
Levitra does not affect visual acuity and contrast perception.
In some patients, 1 hour after taking the drug at a dose of 100 mg
, a slight and transient violation of color discrimination (blue / green) was detected using a test
Farnsworth-Munsell 100; 2 hours after taking the drug, these changes were absent.
The alleged mechanism of color vision impairment is considered to be the suppression of PDE6,
which is involved in the process of light transmission in the retina. In vitro studies
It was shown that the effect of sildenafil on PDE6 is 10 times inferior to its activity
against PDE5.

In vitro studies indicate that the activity of Levitra

against PDE5 is 10 to 10,000 times higher than its activity against other
phosphodiesterase isoforms (PDE 1, 2, 3, 4 and 6). In particular, the activity of sildenafil
against PDE5 is 4,000 times higher than its activity against PDE3 - cAMP-specific
phosphodiesterase involved in cardiac contraction.

Additional information about clinical trials

The efficacy and safety of Levitra was studied in 21 randomized,
double-blind, placebo-controlled trials lasting up to 6 months. Levitra
it was used in more than 3,000 patients with erectile dysfunction of various etiologies
(organic, psychogenic, mixed) aged from 19 to 87 years. The effectiveness
was determined on the basis of a general assessment, diaries, erection registration, an assessment
of the international index of erectile function (IIEF, a questionnaire designed to
assess sexual function) and a survey of partners.
The effectiveness of Levitra, which was evaluated by the ability of the drug
to ensure the onset and preservation of an erection sufficient for sexual intercourse,
was demonstrated in all 21 studies and persisted with prolonged
treatment (one year).

When using the drug in fixed doses, the proportion of patients who
noted an improvement in erectile function was 62% (25 mg), 74% (50 mg)
and 82% (100 mg), and when taking a placebo – 25%. In addition to improving erectile function,
the IIEF analysis showed that Levitra treatment also improves orgasm,
sexual satisfaction and overall satisfaction.
In all studies, the proportion of diabetic patients who noted
an improvement in Levitra treatment was 59%, patients who underwent radical
prostatectomy – 43%, patients with spinal cord injury – 83% (vs. 16%, 15%
and 12% of patients receiving placebo, respectively).


Levitra is quickly absorbed. The concentration of the drug in plasma after
ingestion on an empty stomach reaches a peak within 30-120 minutes (on average 60
minutes). The absolute bioavailability when ingested averages 41% (25-63%).
Pharmacokinetics of Levitra when ingested in the recommended dose range (25-100
mg) is linear.